Department of Pathology, The Third Affiliated Hospital of Guangzhou Medical University, 63 Duobao Road, Guangzhou, 510150, China.
The Third Clinical School of Guangzhou Medical University, Guangzhou, 510150, China.
Mol Biol Rep. 2020 Jun;47(6):4587-4629. doi: 10.1007/s11033-020-05435-1. Epub 2020 Apr 24.
Given that the PI3K/AKT pathway has manifested its compelling influence on multiple cellular process, we further review the roles of hyperactivation of PI3K/AKT pathway in various human cancers. We state the abnormalities of PI3K/AKT pathway in different cancers, which are closely related with tumorigenesis, proliferation, growth, apoptosis, invasion, metastasis, epithelial-mesenchymal transition, stem-like phenotype, immune microenvironment and drug resistance of cancer cells. In addition, we investigated the current clinical trials of inhibitors against PI3K/AKT pathway in cancers and found that the clinical efficacy of these inhibitors as monotherapy has so far been limited despite of the promising preclinical activity, which means combinations of targeted therapy may achieve better efficacies in cancers. In short, we hope to feature PI3K/AKT pathway in cancers to the clinic and bring the new promising to patients for targeted therapies.
鉴于 PI3K/AKT 通路已经表现出对多种细胞过程的强烈影响，我们进一步回顾了 PI3K/AKT 通路的过度激活在各种人类癌症中的作用。我们指出了不同癌症中 PI3K/AKT 通路的异常，这些异常与肿瘤发生、增殖、生长、凋亡、侵袭、转移、上皮-间充质转化、肿瘤细胞的干性表型、免疫微环境和耐药性密切相关。此外，我们研究了目前针对癌症中 PI3K/AKT 通路抑制剂的临床试验，发现尽管这些抑制剂在临床前具有很好的活性，但作为单一疗法的临床疗效迄今为止仍然有限，这意味着靶向治疗的联合可能会在癌症治疗中取得更好的疗效。总之，我们希望将 PI3K/AKT 通路在癌症中的作用推向临床，并为患者带来新的靶向治疗希望。
